Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.
Azizi
Amedeo A
AA
Department of Paediatrics, Medical University of Vienna, Währinger Gürtel 18-20, A-1097 Vienna, Austria.
Haberler
Christine
C
Czech
Thomas
T
Gupper
Astrid
A
Prayer
Daniela
D
Breitschopf
Helene
H
Acker
Till
T
Slavc
Irene
I
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D008297:Male; D019042:Muscle Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009367:Neoplasm Staging; D016658:Psoas Muscles; D012333:RNA, Messenger / Q000378:metabolism; D018234:Sarcoma, Alveolar Soft Part / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012333:RNA, Messenger; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab